

OncoPROSTATE Dx - Final Report

Patient Information

Identification Data

HRN: PRO00000061
ID Card: Unknown

Personal Data

Race: Other
Age: 61

Comorbidities

BPH: Unknown
Prostatic Infarction: Unknown
Prostatitis: Unknown
Urinary Tract Infection: Unknown

Serum Tumor Markers

Total PSA (ng/mL): 21.40
fPSA (ng/mL): 1.90
p2PSA (pg/mL): 16.30
hK2 (ng/mL): 0.11

Blood Drawn Realization

Blood Drawn Date: 19-11-2017

Urine Tumor Markers

Post-DRE PCA3: Negative
Post-DRE T2:ERG: Negative


Urine Drawn Realization

Urine Drawn Date: 19-11-2017

Outcome

Tumor Markers Results

Some Tumor Markers are outside the reference range but do not suggest malignancy.



Comments

Although there is some unknown Prostate related comorbidity that could be a well-known source of False Positive (FP) in healthy patients by increasing PSA levels, whole Tumor Markers recommend that PSA can not be used to calculate risk (most probably because a silent Benign Prostatic Hyperplasia or Prostatitis, among others). However, whole Tumor Markers levels suggest also to discard malignancy (independently of having or not some of these comorbidities).

Conclusions

WE SUGGEST TO DISCARD MALIGNANCY.

This report has been generated from the data entered on 19-11-2017 19:55:27 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Prostate Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 81.7%, Specificity = 98.2%, PPV = 96.8%, NPV = 98.0%. Please note, negativity of the Tumor Markers does not exclude at 100% the


Bioprognos SL

Benet Mateu, 40 - 08034 Barcelona (Spain)
Email: info@bioprognos.com
Website: www.bioprognos.com



Technical Responsible

Lorena Lendinez
Chief Scientific Officer
Bioprognos SL



possibility of a malignant epithelial tumor.